La catena delle opzioni mostra i dati chiave delle opzioni azionarie di TLGY Acquisition a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per TLGY Acquisition..

TLGY Acquisition (OTC:TLGUF) Azioni, Catena delle Opzioni

TLGY Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

TLGY Acquisition Corp Units (1 Ord Class A & 1/2 War)

TLGY Acquisition Corp

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday.
The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&amp;P 500 also rose, gaining, 0.86% to 5,894.52.
Check This Out: <a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares jumped by 2.3% on Tuesday.
In trading on Tuesday, health care stocks fell by 2.5%.
Top Headline
Consumer prices in the U.S. eased faster than expected in April, with fresh tariffs introduced by President Donald Trump appearing not to have a swift and tangible impact on the cost of living.
The Consumer Price Index (CPI) was 2.3% higher compared to a year ago, the Bureau of Labor Statistics said Tuesday, compared to economists&#8217; expectations of 2.4% and the previous reading.
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet falling short of a 0.3% forecasted.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 165% to $14.01 after the company announced it presented studies on HCW9206.</li>
<li>Shares of Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) got a boost, surging 33% to $3.1749 after the company reported better-than-expected first-quarter sales results.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares were also up, gaining 116% to $1.6001 after the company issued a year-over-year increase in its FY25 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) shares dropped 17% to $29.90 following first-quarter financial results.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 81% to $0.1345 after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) was down, falling 26% to $49.26. Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and announced a $47 price target.</li>
</ul>
Commodities In commodity news, oil traded up 2.9% to $63.75 while gold traded up 0.8% at $3,253.80.
Silver traded up 1.6% to $33.130 on Tuesday, while copper rose 2.1% to $4.7180.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.12%, while Spain's IBEX 35 Index rose 0.83%. London's FTSE 100 fell 0.02%, Germany's DAX 40 gained 0.31% and France's CAC 40 gained 0.30% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.43%, Hong Kong's Hang Seng Index dipping 1.87%, China's Shanghai Composite Index gaining 0.17% and India's BSE Sensex falling 1.55%.
Economics
The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of 2.4%.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AFMD

HALO

HCWB

LOBO

MVST

XENE

Crude Oil Gains 3%; US Inflation Eases In April

Craig-Hallum analyst Christian Schwab maintains Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) with a Buy and lowers the price target from $12 to $10.

Price Target

Analyst Ratings

MRVI

Craig-Hallum Maintains Buy on Maravai LifeSciences, Lowers Price Target to $10

<a href="https://www.bloomberg.com/news/articles/2025-05-13/petrobras-ceo-vows-belt-tightening-to-navigate-lower-oil-prices?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-13/petrobras-ceo-vows-belt-tightening-to-navigate-lower-oil-prices?embedded-checkout=true</a>

General

'Petrobras CEO Vows Belt Tightening to Navigate Lower Oil Prices'- Bloomberg

Craig-Hallum analyst Anthony Stoss maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and lowers the price target from $8 to $6.

INDI

Craig-Hallum Maintains Buy on Indie Semiconductor, Lowers Price Target to $6

CIFR

Engie North America Partners With Cipher Mining To Enter Into A Power Supply Agreement To Power A Cipher Data Center In Texas; Once Executed, The Agreement Would Allow Cipher To Purchase Up To 300MW Of Clean Energy From One Of Engie's Wind Facilities

ACELYRIN, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction.
ACELYRIN expects to complete the transaction in the second quarter of 2025.

ALMS

SLRN

ACELYRIN Stockholders Approve Merger With Alumis, Securing 0.4814 Shares Per ACELYRIN Share At Closing

Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Strata Skin Sciences will report an earnings per share (EPS) of $-0.44.
Investors in Strata Skin Sciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.23 in the last quarter, leading to a 0.74% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1747156042_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Strata Skin Sciences were trading at $2.55 as of May 09. Over the last 52-week period, shares are down 39.29%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Take on Strata Skin Sciences</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Strata Skin Sciences.
With 1 analyst ratings, Strata Skin Sciences has a consensus rating of Buy. The average one-year price target is $6.0, indicating a potential 135.29% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Co-Diagnostics and Ekso Bionics Holdings, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Co-Diagnostics, with an average 1-year price target of $5.5, suggesting a potential 115.69% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ekso Bionics Holdings, with an average 1-year price target of $4.67, suggesting a potential 83.14% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Co-Diagnostics and Ekso Bionics Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strata Skin Sciences</td>
<td>Buy</td>
<td>10.21%</td>
<td>$5.76M</td>
<td>-62.83%</td>
</tr>
<tr>
<td>Co-Diagnostics</td>
<td>Buy</td>
<td>-95.80%</td>
<td>$-105.74K</td>
<td>-18.68%</td>
</tr>
<tr>
<td>Ekso Bionics Holdings</td>
<td>Buy</td>
<td>-10.14%</td>
<td>$1.81M</td>
<td>-24.54%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Strata Skin Sciences ranks highest in Revenue Growth among its peers. It has the highest Gross Profit margin. However, it has the lowest Return on Equity.
<h3>Delving into Strata Skin Sciences's Background</h3>
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
<h3>Financial Insights: Strata Skin Sciences</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Strata Skin Sciences showcased positive performance, achieving a revenue growth rate of 10.21% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Strata Skin Sciences's net margin is impressive, surpassing industry averages. With a net margin of -46.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Strata Skin Sciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -62.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Strata Skin Sciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -11.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.31, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/SSKN/earnings">To track all earnings releases for Strata Skin Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SSKN

A Peek at Strata Skin Sciences's Future Earnings

PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) will release its quarterly earnings report on Wednesday, 2025-05-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate PDS Biotechnology to report an earnings per share (EPS) of $-0.22.
The market awaits PDS Biotechnology's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 0.8% increase in the share price on the subsequent day.
Here's a look at PDS Biotechnology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.28</td>
<td>-0.28</td>
<td>-0.34</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.29</td>
<td>-0.23</td>
<td>-0.30</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-11.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747156017_0.png" alt="eps graph" />
<h3>PDS Biotechnology Share Price Analysis</h3>
Shares of PDS Biotechnology were trading at $1.29 as of May 12. Over the last 52-week period, shares are down 64.03%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PDSB/earnings">To track all earnings releases for PDS Biotechnology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PDSB

Insights Ahead: PDS Biotechnology's Quarterly Earnings

<h3>Gainers</h3>
<ul>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock rose 105.9% to $1.56 during Tuesday's regular session. The company's market cap stands at $13.5 million. </li>
<li>Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) stock rose 60.15% to $11.23. The market value of their outstanding shares is at $409.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) stock rose 21.76% to $1.79. The market value of their outstanding shares is at $54.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) stock increased by 18.31% to $1.2. The market value of their outstanding shares is at $27.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares decreased by 26.5% to $21.32 during Tuesday's regular session. The market value of their outstanding shares is at $380.1 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares decreased by 22.17% to $1.58. The company's market cap stands at $425.5 million. </li>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) shares fell 20.52% to $0.64. The company's market cap stands at $18.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) shares decreased by 18.48% to $0.95. The company's market cap stands at $28.5 million. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares fell 17.82% to $0.31. The company's market cap stands at $25.0 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) shares declined by 13.79% to $13.38. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BGFV

CLEU

CNTY

LSEA

NTCL

QVCGP

TLYS

10 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 91.4% to $0.03 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

AXDX

CELU

CNSP

HUMA

PLRZ

SGMO

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect eGain to report an earnings per share (EPS) of $0.07.
Anticipation surrounds eGain's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.02, leading to a 18.18% drop in the share price the following trading session.
Here's a look at eGain's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>0</td>
<td>0.02</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.04</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-18.0%</td>
<td>-7.000000000000001%</td>
<td>-14.000000000000002%</td>
<td>-13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747156001_0.png" alt="eps graph" />
<h3>Performance of eGain Shares</h3>
Shares of eGain were trading at $5.1 as of May 12. Over the last 52-week period, shares are down 12.65%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/EGAN/earnings">To track all earnings releases for eGain visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EGAN

Earnings Preview: eGain

<h3>Gainers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock rose 112.1% to $7.38 during Tuesday's regular session. The company's market cap stands at $4.4 million. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares moved upwards by 39.63% to $10.78. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock rose 37.9% to $0.59. The company's market cap stands at $32.5 million. </li>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) stock moved upwards by 31.99% to $3.15. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) stock moved upwards by 31.26% to $6.13. The market value of their outstanding shares is at $69.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) shares increased by 27.84% to $5.95. The company's market cap stands at $176.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) stock declined by 25.2% to $1.91 during Tuesday's regular session. The company's market cap stands at $258.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares declined by 23.05% to $6.02. The market value of their outstanding shares is at $45.6 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares declined by 16.48% to $1.45. The market value of their outstanding shares is at $175.3 million. </li>
<li>Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares declined by 15.57% to $5.86. The company's market cap stands at $1.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) stock declined by 14.16% to $0.14. The company's market cap stands at $6.9 million. </li>
<li>Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) shares declined by 11.85% to $0.76. The market value of their outstanding shares is at $78.2 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLNK

BURU

BWNB

HTCO

LICN

Nuveen Insured California Premium Fund Ii

RAIN

VTSI

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) shares rose 24.5% to $61.63 during Tuesday's regular session. The company's market cap stands at $4.7 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) stock moved upwards by 21.93% to $190.47. The market value of their outstanding shares is at $20.4 billion. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares increased by 20.27% to $7.86. The market value of their outstanding shares is at $74.0 million. </li>
<li>Electro-Sensors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELSE#NASDAQ">ELSE</a>) shares increased by 19.39% to $5.01. The company's market cap stands at $17.2 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) stock moved upwards by 18.87% to $4.22. The market value of their outstanding shares is at $70.5 million. </li>
<li>Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) stock moved upwards by 18.8% to $2.5. The company's market cap stands at $190.2 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Exodus Movement (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#AMEX">EXOD</a>) shares decreased by 25.8% to $40.27 during Tuesday's regular session. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock declined by 22.35% to $2.43. The market value of their outstanding shares is at $24.2 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares decreased by 19.47% to $1.2. The company's market cap stands at $5.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) shares declined by 17.11% to $4.75. The company's market cap stands at $169.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) stock decreased by 16.63% to $3.16. The market value of their outstanding shares is at $7.4 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares fell 14.68% to $0.29. The company's market cap stands at $8.6 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

ELSE

EXOD

FSLR

MASS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MLGO

SONM

TZUP

VUZI

12 Information Technology Stocks Moving In Tuesday's Intraday Session

WIIM

Boeing shares are trading higher after AviLease placed an order for Boeing 737 MAX jets.

Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Aterian to report an earnings per share (EPS) of $-0.70.
Aterian bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.45, leading to a 27.96% increase in the share price the following trading session.

<img src="https://www.benzinga.com/files/images/story/2025/1747155918_0.png" alt="eps graph" />
<h3>Aterian Share Price Analysis</h3>
Shares of Aterian were trading at $2.18 as of May 12. Over the last 52-week period, shares are down 31.09%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ATER/earnings">To track all earnings releases for Aterian visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATER

Exploring Aterian's Earnings Expectations

Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Luminar Technologies will report an earnings per share (EPS) of $-1.63.
Investors in Luminar Technologies are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.75, which was followed by a 32.96% increase in the share price the next day.
Here's a look at Luminar Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.17</td>
<td>-2.55</td>
<td>-2.85</td>
<td>-3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.42</td>
<td>-2.40</td>
<td>-2.70</td>
<td>-2.85</td>
</tr>
<tr>
<td>Price Change %</td>
<td>33.0%</td>
<td>11.0%</td>
<td>-37.0%</td>
<td>19.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747155899_0.png" alt="eps graph" />
<h3>Tracking Luminar Technologies's Stock Performance</h3>
Shares of Luminar Technologies were trading at $4.6 as of May 12. Over the last 52-week period, shares are down 82.94%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/LAZR/earnings">To track all earnings releases for Luminar Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LAZR

What to Expect from Luminar Technologies's Earnings

Benchmark analyst Nathan Martin maintains Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) with a Buy and lowers the price target from $18 to $14.

METC

Benchmark Maintains Buy on Ramaco Resources, Lowers Price Target to $14

Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) will release its quarterly earnings report on Wednesday, 2025-05-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Creative Realities to report an earnings per share (EPS) of $-0.12.
The announcement from Creative Realities is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.16, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Creative Realities's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.02</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>0.01</td>
<td>-0.06</td>
<td>-0.01</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-11.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747155878_0.png" alt="eps graph" />
<h3>Market Performance of Creative Realities's Stock</h3>
Shares of Creative Realities were trading at $1.66 as of May 12. Over the last 52-week period, shares are down 52.16%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CREX/earnings">To track all earnings releases for Creative Realities visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CREX

Examining the Future: Creative Realities's Earnings Outlook

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.taskus.com%2Fen-us%2F&amp;esheet=54254082&amp;newsitemid=20250513328260&amp;lan=en-US&amp;anchor=TaskUs%2C+Inc.&amp;index=1&amp;md5=7c4207ec4c264caca3f5c34bad83f3c0">TaskUs, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>), a leading provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, today announced strategic partnerships with Decagon and Regal. Together with these two elite agentic AI platform companies, TaskUs will aim to further transform customer support through intelligent automation.
The partnerships with Decagon and Regal augments TaskUs' <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.taskus.com%2Fpress-release%2Ftaskus-launches-agentic-ai-consulting-practice-to-lead-businesses-through-the-ai-era%2F&amp;esheet=54254082&amp;newsitemid=20250513328260&amp;lan=en-US&amp;anchor=recently+announced&amp;index=2&amp;md5=d3a960e473b68c19e755330023b39f69">recently announced</a> agentic AI consulting practice, a set of business services and expertise that help companies seamlessly integrate advanced AI technologies into their customer experience operations.

TASK

TaskUs Announces Strategic Partnerships With Decagon And Regal To Further Transform Customer Support Through Intelligent Automation

Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Grove Collaborative Hldgs will report an earnings per share (EPS) of $-0.04.
Anticipation surrounds Grove Collaborative Hldgs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.06 in the last quarter, leading to a 2.41% drop in the share price on the following day.
Here's a look at Grove Collaborative Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.13</td>
<td>-0.14</td>
<td>-0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.21</td>
<td>-0.04</td>
<td>-0.28</td>
<td>-0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-12.0%</td>
<td>-6.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747155822_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Grove Collaborative Hldgs were trading at $1.22 as of May 12. Over the last 52-week period, shares are down 22.23%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/GROV/earnings">To track all earnings releases for Grove Collaborative Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

TLGY Acquisition

TLGY Acquisition (TLGUF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO